Kirin Holdings Company, Limited Sponsored ADR (KNBWY) – Globe Newswire
-
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
-
Kyowa Kirin to Acquire Orchard Therapeutics
-
Tenapanor for Hyperphosphatemia Approved in Japan
-
Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors
-
InveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic Areas
-
InveniAI and Kyowa Kirin Enter AI-Powered Novel Target Discovery Collaboration
-
Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)
-
Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)
-
Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) in Tumor-Induced Osteomalacia (TIO)
Back to KNBWY Stock Lookup